pd 98059 has been researched along with (3S,5S,6E)-7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Abe, H; Furuno, Y; Kabashima, N; Matsumoto, M; Miyamoto, T; Miyazaki, M; Okazaki, M; Otsuji, Y; Serino, R; Shibata, T; Takeuchi, M; Tamura, M; Tokunaga, M | 1 |
1 other study(ies) available for pd 98059 and (3S,5S,6E)-7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid
| Article | Year |
|---|---|
Fluvastatin attenuates IGF-1-induced ERK1/2 activation and cell proliferation by mevalonic acid depletion in human mesangial cells.
Topics: Blotting, Western; Cell Proliferation; Fatty Acids, Monounsaturated; Flavonoids; Fluvastatin; Glomerular Mesangium; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Insulin-Like Growth Factor I; Mevalonic Acid; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Mitogen-Activated Protein Kinase Kinases; Phosphorylation; Signal Transduction | 2009 |